Global Alzheimer’s Disease Therapeutics And Diagnostic Market

1
The Global Alzheimers Disease Therapeutics and
Diagnostics Market to Progress with 5.56 of CAGR
by 2028

• Triton Market Research presents the Global
  Alzheimer s Disease Therapeutics and Diagnostics
  Market report segmented by Therapeutics and
  Diagnostics (Therapeutics Therapeutics by Drugs
  Marketed Drugs, Pipeline Drugs, Therapeutics by
  Disease Stage Late Stage Severe AD,
  Early/Middle Stage Mild to Moderate AD,
  Prodromal Stage, Therapeutics by Generic and
  Branded Branded, Generic, Diagnostics Lumbar
  Puncture Test, Positron Emission Tomography
  (PET), Electroencephalography, Magnetic Resonance
  Imaging, Computed Tomography, Blood Test, Other
  Diagnostics) and by Geographical Region (North
  America, Europe, Asia-Pacific, Latin America, the
  Middle East and Africa), discussing Market
  Summary, Industry Outlook, Key Insights, Impact
  of COVID-19, Porters Five Forces Analysis, Key
  Buying Impact Analysis, Industry Components,
  Different Phases Of Alzheimers Disease, Market
  Attractiveness Index, Vendor Scorecard, Key
  Strategic Developments, Drivers, Challenges,
  Opportunities, Competitive Landscape, Research
  Methodology Scope, Global Market Size,
  Forecasts Analysis (2021-2028).
• Triton Market Research, in its report on the
  Global Alzheimers Disease Therapeutics and
  Diagnostics Market, implies that this industry is
  expected to progress at a CAGR of 5.56 during
  the forecasting period (2021-2028).

2
Request Free sample https//www.tritonmarketresea
rch.com/reports/alzheimers-disease-therapeutics-an
d-diagnostic- marketrequest-free-sample
As per estimates, nearly 5.8 million people in
the United States have Alzheimers dementia. By
2050, this number is expected to rise to 13.8
million. Thus, the growing prevalence of dementia
in developing countries is a major factor that is
expected to fuel the growth of the market in the
coming years. However, the failure of the
late-stage drugs to induce significant
improvement of symptoms and stringent regulations
regarding drug development and clinical trials
are hampering the market growth process. The
market in North America currently leads the
global market, with the largest share. It is
expected to continue its stronghold in the years
to come. There is a high population comprising
elderly adults present in the region, who form a
major patient base for dementia and Alzheimers.
This has led to an increased demand for AD
therapeutics and diagnostics here. Moreover,
there are several research studies being
conducted in the US for the development of novel
therapeutics and diagnostics for the disease,
which are being supported by new product
launches. For instance, C2N Diagnostics launched
PrecivityAD in November 2020, which is the
worlds first blood test to measure amyloid
levels in the blood for Alzheimers diagnosis.
All these factors are anticipated to boost the
studied market growth in the region. Sun
Pharmaceuticals Industries Ltd, Zydus Cadila,
Allergan Plc acquired by Abbvie, Biogen Inc,
Pfizer Inc, Teva Pharmaceutical Industries
Limited, Luye Pharma Group, GE Healthcare, Eli
Lilly Company, Cognoptix Inc, Eisai Co Ltd,
Amarantus Bioscience Holdings Inc, Siemens
Healthineers AG, Novartis AG, F Hoffmann La
Roche, Lupin Limited, Merck Co Inc, Baxter
International Inc, PeopleBio Co, and Johnson
Johnson are the eminent players present in this
market. The competition among players in this
industry has increased significantly with the
introduction of generics. Furthermore, this
industry is also observing meaningful strategic
collaborations among different players. For
instance, Johnson Johnson and GE Healthcare
have formed entered into a partnership for a
project that aims to find pre-symptomatic
biomarkers for AD. Recent developments with
respect to regulatory guidelines and disease
biomarkers are expected to open new gateways for
innovation in this field, which is expected to
generate opportunities for new players to step
into this market.
Contact Us sales_at_tritonmarketresearch.com Phone
44 7441 911839